AstraZeneca's defining moves.
The defining strategic moves at AstraZeneca — each one explained and grounded in the record.
The Turnaround · Decision Forks
AstraZeneca Said No to £55 a Share on a Pipeline That Didn't Exist Yet
In 2014 AstraZeneca rejected Pfizer's final £55-a-share proposal, valuing it near £69.4 billion. The board called it too cheap. A decade later, $54.1 billion in 2024 revenue made them right - but they were betting on an oncology business that was barely born.
8 min
The Counterfactual · Decision Forks
AstraZeneca Turned Down $117 Billion. The Real Reason Wasn't the Money.
In 2014 Pfizer chased AstraZeneca with four rising offers, ending at £55 a share - roughly $117 billion. The board said no. The price gap was real, but the deeper objection was that Pfizer was buying a tax address, and AstraZeneca was selling a pipeline.
8 min
The Counterfactual · Decision Forks
AstraZeneca Turned Down $117 Billion. The Real Reason Wasn't the One the Board Gave.
In May 2014 AstraZeneca rejected Pfizer's £55-a-share, ~$117bn offer and was praised for management conviction. The board cited price. The stronger case was that Pfizer's deal was a tax-inversion vehicle whose legislative risk would have gutted the value — and the counterfactual cost to shareholders was effectively zero.
8 min
The Turnaround · Decision Forks
AstraZeneca Turned Down $117 Billion to Bet on Drugs It Hadn't Invented Yet
In 2014 AstraZeneca rejected Pfizer's £69.4 billion ($117 billion) offer and promised $45 billion of revenue by 2023 instead. It hit the number - one year of COVID money and two patent cliffs later.
8 min